These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514 [TBL] [Abstract][Full Text] [Related]
6. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165 [TBL] [Abstract][Full Text] [Related]
7. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837 [TBL] [Abstract][Full Text] [Related]
8. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515 [TBL] [Abstract][Full Text] [Related]
9. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778 [TBL] [Abstract][Full Text] [Related]
10. Investigating the Role of DUSP4 in Uveal Melanoma. Aughton K; Sabat-Pospiech D; Barlow S; Coupland SE; Kalirai H Transl Vis Sci Technol; 2022 Dec; 11(12):13. PubMed ID: 36576731 [TBL] [Abstract][Full Text] [Related]
11. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
12. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Gutierrez-Prat N; Zuberer HL; Mangano L; Karimaddini Z; Wolf L; Tyanova S; Wellinger LC; Marbach D; Griesser V; Pettazzoni P; Bischoff JR; Rohle D; Palladino C; Vivanco I Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35580987 [TBL] [Abstract][Full Text] [Related]
13. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351 [TBL] [Abstract][Full Text] [Related]
14. An overview of binimetinib for the treatment of melanoma. Specenier P Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585 [TBL] [Abstract][Full Text] [Related]
15. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
16. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237 [TBL] [Abstract][Full Text] [Related]